medigraphic.com
ISSN 1561-3119 (Electronic)

2013, Number 2

<< Back Next >>

Rev Cubana Pediatr 2013; 85 (2)

Therapeutic applications of human immunoglobulines in Pediatrics

Noda AAL, Vidal TLA, Rodríguez RB

Language: Spanish
References: 50
Page: 230-241
PDF size: 64.58 Kb.


ABSTRACT

There are presently several pharmaceuticals made up of immunoglobulines (fundamentally IgG) purified by several methods, which means that they can be administered by different routes (intramuscularly, intravenously and subcutaneously). These products have a wide spectrum of prescriptions for several diseases. The immunoglobulins are the final effectors of the humoral immune response, so their fundamental prescriptions cover replacement therapies in diseases with antibody production deficit, situations requiring immediate presence of neutralizing antibodies such as post-exposure therapies, and diseases with immune response deregulation.


REFERENCES

  1. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M. Preparation and properties of serum and plasma proteins III: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459-75.

  2. Oncley JL, Melin M, Richert DA, Cameron JW, Gross PM. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71:541-50.

  3. Bruton OC. Agammaglobulinema. Pediatrics. 1952;9:722-7.

  4. Hooper JA. Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations. Immunol Allergy Clin N Am. 2008;28:765-78.

  5. Raab CP. Passive Immunization. Prim Care Clin Office Pract. 2011;38:681-91.

  6. Orenstein WA, Pickering LK. Immunization Practices. In: Kliegman RM, Stanton BF, Schor NF, Geme JW, Behrman RE, editors. Nelson textbook of pediatrics. 19th edition. Philadelphia: Elsevier; 2011. p. 881-95.

  7. Stiehm ER. Appropriate Therapeutic Use of Immunoglobulin. Transfusion Medicine Reviews. 1996;X(3):203-21.

  8. Bonilla FA. Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes. Immunol Allergy Clin N Am. 2008;28:803-19.

  9. Kim W. Immunology and Allergy. In: Tschudy MM, Arcara KM, editors. Johns Hopkins: The Harriet Lane Handbook. 19th edition. Philadelphia: Elsevier; 2011. p. 354-69.

  10. Bell BP, Fiore AE. Hepatitis A Virus. In: Long SS, Pickering LK, Prober ChG, editors. Principles and Practice of Pediatric Infectious Diseases. 3rd edition. Philadelphia: Churchill Livingstone; 2008. p. 1157-62.

  11. Wasley A, Feinstone SM, Bell BP. Hepatitis A Virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 7th edition. Philadelphia: Churchill Livingstone; 2009. p. 2367-87.

  12. Centers for Disease Control and Prevention. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(41):1080-4.

  13. Nguyen CT, Tran TT. Hepatitis Vaccination and Prophylaxis. Clin Liver Dis. 2009;13:317-29.

  14. Brundage SC, Fitzpatrick NA. Hepatitis A. Am Fam Physician. 2006;73:2162-8.

  15. Gershon AA. Measles Virus (Rubeola). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 7th edition. Philadelphia: Churchill Livingstone; 2009. p. 2229-387.

  16. Mason WH. Measles. In: Kliegman RM, Stanton BF, Schor NF, Geme JW, Behrman RE, editors. Nelson textbook of pediatrics. 19th edition. Philadelphia: Elsevier; 2011. p. 1069-75.

  17. Maldonado YA. Rubella Virus. In: Long SS, Pickering LK, Prober ChG, editors. Principles and Practice of Pediatric Infectious Diseases. 3rd edition. Philadelphia: Churchill Livingstone; 2008. p. 1096-101.

  18. Centers for Disease Control and Prevention. Measles, mumps and rubella: vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 1998;47:1-57.

  19. Berger M. Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin N Am. 2008;28:413-37.

  20. Gonik B. Passive immunization: the forgotten arm of immunologically based strategies for disease containment. Am J Obstet Gynecol. 2011;205:444.e1-444.e6.

  21. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33.

  22. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlerdacha B, Guerra M, et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1-28.

  23. World Health Organization. WHO recommendations on rabies post-exposure treatment and the correct technique. 1. Guide for rabies post-exposure treatment. Geneva (Switzerland): World Health Organization; 1997. p. 1-10.

  24. Grundbacher FJ. Behring's discovery of diphtheria and tetanus antitoxins. Immunol Today. 1992;13:188-90.

  25. Kak V, Sundareshan V, Modi J, Khardori NM. Immunotherapies in Infectious Diseases. Med Clin N Am. 2012;96:455-74.

  26. Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med. 1969;280:1191-4.

  27. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40.

  28. Orange JS, Hossny EM, Catherine R. Weiler CR, Ballow M, Berger M, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525-53.

  29. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders. Neurology. 2012;78:1009-15.

  30. Silvergleid AJ, Berger M. General principles in the use of immune globulin [homepage en Internet] [citado 14 de agosto de 2012]. Disponible en: http://www.uptodate.com/contents/general-principles-in-the-use-of-immune globulin?source=search_result&search=Intravenous+Immunoglobulin&selected Title=2%7E150

  31. Ferrara G, Zumla A, Maeurer M. Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections. The American Journal of Medicine. 2012;10:1-8.

  32. Buckley RH. Primary Defects of Antibody Production. In: Kliegman RM, Stanton BF, Schor NF, Geme JW, Behrman RE, editors. Nelson textbook of pediatrics. 19th edition. Philadelphia: Elsevier; 2011. p. 722-8.

  33. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:S182-94.

  34. Berger M. Immune globulin therapy in primary immunodeficiency [homepage en Internet] [citado 14 de agosto de 2012]. Disponible en: http://www.uptodate.com/contents/immune-globulin-therapy-in-primary-immunodeficiency?source=see_link

  35. Deener A, Mehra A, Bernstein L, Shliozberg J, Rubinstein A. Intravenous Gammaglobulin Treatment in HIV-1 Infection. Immunol Allergy Clin N Am. 2008;28:851-9.

  36. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village: American Academy of Pediatrics; 2006. p. 378-401.

  37. Anaissie E. Prophylaxis of infections in hematopoietic cell transplant recipients [homepage en Internet] [citado 14 de agosto de 2012]. Disponible en: http://www.uptodate.com/contents/prophylaxis-of-infections-in-hematopoietic-cell-transplant-recipients?source=see_link&anchor=H37#H37

  38. Noda Albelo AL, Rodríguez Ramos B, Vidal Tallet LA. Mecanismos de acción de la gammaglobulina para uso endovenoso. Rev Cubana Hematol Inmunol Hemoter. 2002;18(1):41-7.

  39. Lee SJ, Chinen J, Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusión proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol. 2010;125:S314-23.

  40. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV. Intravenous immunoglobulins-understanding properties and mechanisms. Clin Exp Immunol. 2009;158(Suppl 1):2-13.

  41. Blanchette V, Bolton-Maggs P. Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management. Hematol Oncol Clin N Am. 2010;24:249-73.

  42. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010;22:551-60.

  43. Vidal Tallet LA, Noda Albelo AL, Casal Menéndez AX, Sánchez Hernández CA, Montell Hernández OA, Linares Álvarez l. Enfermedad de Kawasaki. Aspectos a considerar. Rev Med Electrón [serie en Internet]. 2010 [citado 13 de agosto de 2012];32(4). Disponible en: http://scielo.sld.cu/scielo.php?pid=S1684-18242010000400007&script=sci_arttext

  44. Scuccimarri R. Kawasaki Disease. Pediatr Clin N Am. 2012;59:425-45.

  45. Vella J, Bennett WM, Brennan DC. Cytomegalovirus infection in renal transplant recipients [homepage en Internet] [citado 14 de agosto de 2012]. Disponible en: http://www.uptodate.com/contents/cytomegalovirus-infection-in-renal-transplant-recipients?source=search_result&search=Cytomegalovirus+infection+in+renal+transplant+recipients&selectedTitle=1%7E15

  46. Crowe JE. Respiratory Syncytial Virus. In: Kliegman RM, Stanton BF, Schor NF, Geme JW, Behrman RE, editors. Nelson textbook of pediatrics. 19th edition. Philadelphia: Elsevier; 2011. p. 1126-9.

  47. Reddy P, Bleck TP Clostridium botulinum (Botulism). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th edition. Philadelphia: Churchill Livingstone; 2009. p. 3097-102.

  48. Hsu JL, Safdar N. Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases. Infect Dis Clin N Am. 2011;25:773-88.

  49. Haddad A, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46(3):315-21.

  50. Berger M. Subcutaneous Administration of IgG. Immunol Allergy Clin N Am. 2008;28:779-802.




2020     |     www.medigraphic.com